SOURCE: DNAPrint Genomics, Inc.

April 11, 2007 07:00 ET

DNAPrint® Genomics Filing SB-2

SARASOTA, FL -- (MARKET WIRE) -- April 11, 2007 --DNAPrint® Genomics, Inc. (OTCBB: DNAG) today announced that it will be filing a registration statement with the Securities and Exchange Commission to register 150,000,000 shares to be issued under an Investment Agreement with Dutchess Private Equities Fund, Ltd. ("Dutchess"). The Dutchess Agreement provides that, from time to time, DNAPrint may deliver a notice to Dutchess and Dutchess will purchase DNAPrint shares based upon the parameters of the agreement.

Currently, DNAPrint has effective a registration statement covering approximately 640,000,000 shares issuable under an existing Dutchess agreement that expires May 17, 2007. Shares can be issued under this agreement through May 17, 2007, but once the agreement has expired, none of those 640,000,000 registered shares can be issued. More details on the filing can be found under the Company's name at

"We are pleased to continue our relationship with Dutchess. We are in the process of obtaining additional funding for our research and development activities of our subsidiary, DNAPrint Pharmaceuticals, Inc., but we continue to use the Dutchess funding as well," stated DNAPrint® President and Chief Executive Officer, Richard Gabriel.

About DNAPrint® Genomics, Inc.

DNAPrint® Genomics, Inc. ( is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint® Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to for information on law enforcement and consumer applications which include DNAWitness™, RETINOME™, Ancestry ByDNA™ and EURO-DNA™. DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Contact Information

  • Company Contact:
    Richard Gabriel
    CEO and President
    Ron Stabiner
    The Wall Street Group, Inc.